Edgewise Therapeutics, Inc. (EWTX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 29.04M USD | Liabilities, Current |
| Cash and equivalents | 72.32M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $29.04M | $72.32M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $22.54M | $33.21M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $27.37M | $61.15M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $21.65M | $46.00M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $20.90M | $43.40M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $21.11M | $49.92M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $23.86M | $41.67M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $18.96M | $44.81M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $17.18M | $43.48M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $14.60M | $30.26M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $16.77M | $86.10M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $16.34M | $32.96M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $14.40M | $31.81M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $12.71M | $48.23M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $16.59M | $21.99M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $13.30M | $109.75M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $9.22M | $18.34M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $10.00M | $34.45M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $10.52M | $15.57M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $8.75M | $10.57M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $6.74M | $50.40M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $4.85M | $221.04M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $4.34M | $104.92M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $38.73M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $16.87M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $20.91M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $23.65M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |